IP Library › Granted Patent US 12,629,373
Granted Patent B2
US 12,629,373 · App. 18/935,743 · Granted May 19, 2026

Dietary macro/micronutritional compositions and applications thereof

Inventor: Atif Dabdoub (Atlanta, GA)
Assignee: Atif Dabdoub
A61K31/51A61K31/122A61K31/197A61K31/198A61K31/20A61K31/205A61K31/375A61K31/381A61K31/4188A61K31/4415A61K31/455A61K31/519A61K31/525A61K31/593A61K31/714A61K33/04A61K33/06A61K33/22A61K33/24A61K33/26A61K33/30A61K33/32A61K33/34A61K38/063A61K47/36A61K47/46A61P3/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,629,373
App. No.
18/935,743
Granted
May 19, 2026
Kind
B2
Abstract

Provided herein are compositions composed of a plurality of minerals and vitamins that provide numerous health benefits and quality of life to subjects in need thereof. Also described herein are kits composed of the compositions described herein with a marine omega 3 fatty acid, coenzyme Q10, or a combination thereof. In one aspect, the compositions described herein can treat a subject diagnosed with prediabetes, type 1 diabetes, type 2 diabetes or insulin uptake. In another aspect, the compositions described herein can increase the performance of athletes by relaxing and dilating blood vessels, thus improve circulation as well as shorten the time of recovery after exercises or games. In another aspect, the compositions described herein can improve the well-being and immune response system. It also improves the human system against bacterial and fungal infections. In another aspect, the compositions described herein can treat myalgic encephalomyelitis in a subject. In another aspect, the compositions described herein can reduce or prevent one or more symptoms of Crohn's disease in a subject. In another aspect, the compositions described herein can enhance one or more physical properties of a subject after exercise.

Claims (124)

1 . A method for treating a subject with type I diabetes or type II diabetes or a subject diagnosed with prediabetes, the method comprising administering to the subject a therapeutically effective amount of a composition comprising:

vitamin B1,

vitamin B2,

vitamin B3,

vitamin B5,

vitamin B6,

vitamin B7,

vitamin B9,

vitamin B12,

vitamin C,

vitamin D 3 ,

a pharmaceutically-acceptable compound of calcium,

a pharmaceutically-acceptable compound of magnesium,

a pharmaceutically-acceptable compound of zinc,

a pharmaceutically-acceptable compound of selenium,

a pharmaceutically-acceptable compound of iron, and

a pharmaceutically-acceptable compound of L-carnitine,

wherein the composition does not include vitamin E.

2 . A method for treating a subject with type I diabetes or type II diabetes or a subject diagnosed with prediabetes, the method comprising administering to the subject a therapeutically effective amount of a composition comprising:

vitamin B1,

vitamin B2,

vitamin B3,

vitamin B5,

vitamin B6,

vitamin B7,

vitamin B9,

vitamin B12,

vitamin C,

vitamin D 3 ,

a pharmaceutically-acceptable compound of calcium,

a pharmaceutically-acceptable compound of magnesium,

a pharmaceutically-acceptable compound of zinc,

a pharmaceutically-acceptable compound of selenium,

a pharmaceutically-acceptable compound of iron, and

a pharmaceutically-acceptable compound of L-carnitine,

a pharmaceutically-acceptable compound of cobalt,

red beetroot extract, and a pectin.

3 . The method of claim 1 , wherein the composition treats one or more symptoms of type I diabetes or type II diabetes when compared to the same subject prior to the administration of the composition, wherein the symptom is selected from the group consisting of weight loss, polydipsia, polyuria, polyphagia, blurred vision, headache, fatigue, slow healing of cuts, itchy skin, and any combination thereof.

4 . The method of claim 1 , wherein the composition reduces the amount of insulin required by the subject.

5 . The method of claim 1 , wherein the composition further comprises red beetroot extract and a pectin.

6 . The method of claim 1 , wherein the pectin comprises sugarbeet pectin.

7 . The method of claim 1 , wherein the composition further comprises a pharmaceutically-acceptable compound of chromium and a pectin.

8 . The method of claim 7 , wherein the pectin comprises sugarbeet pectin.

9 . The method of claim 1 , wherein the composition further comprises

a therapeutically effective amount of

a pharmaceutically-acceptable compound of manganese,

a pharmaceutically-acceptable compound of chromium,

a pharmaceutically-acceptable compound of copper, and reduced glutathione.

10 . The method of claim 1 , wherein the subject is further administered a marine omega 3 fatty acid, coenzyme Q10, or a combination thereof.

11 . The method of claim 1 , wherein the composition comprises vitamin B1 in an amount of from about 0.005 weight percent to about 0.10 weight percent of the composition;

vitamin B2 in an amount of from about 0.005 weight percent to about 0.10 weight percent of the composition;

vitamin B3 in an amount of from about 0.05 weight percent to about 0.50 weight percent of the composition;

vitamin B5 in an amount of from about 0.01 weight percent to about 0.50 weight percent of the composition;

vitamin B6 in an amount of from about 0.01 weight percent to about 0.50 weight percent of the composition;

vitamin B7 in an amount of from about 0.010 weight percent to about 0.50 weight percent of the composition;

vitamin B9 in an amount of from about 0.001 weight percent to about 0.10 weight percent of the composition;

vitamin B12 in an amount of from about 0.05 weight percent to about 0.50 weight percent of the composition;

vitamin C in an amount of from about 1.00 weight percent to about 10.00 weight percent of the composition;

vitamin D3 in an amount of from about 0.01 weight percent to about 0.50 weight percent of the composition;

a pharmaceutically-acceptable compound of calcium in an amount of from about 10.00 weight percent to about 35.00 weight percent of the composition;

a pharmaceutically-acceptable compound of magnesium in an amount of from about 15.00 weight percent to about 35.00 weight percent of the composition;

a pharmaceutically-acceptable compound of zinc in an amount of from about 0.10 weight percent to about 2.00 weight percent of the composition;

a pharmaceutically-acceptable compound of selenium in an amount of from about 0.01 weight percent to about 0.50 weight percent of the composition;

a pharmaceutically-acceptable compound of iron in an amount of from about 0.05 weight percent to about 5.00 weight percent of the composition; and

a pharmaceutically-acceptable compound of L-carnitine in an amount of from about 10.00 weight percent to about 30.00 weight percent of the composition.

12 . The method of claim 1 , wherein the composition comprises

vitamin B1 in an amount of from about 0.50 weight percent to about 3.00 weight percent of the composition;

vitamin B2 in an amount of from about 0.50 weight percent to about 3.00 weight percent of the composition;

vitamin B3 in an amount of from about 1.00 weight percent to about 3.00 weight percent of the composition;

vitamin B5 in an amount of from about 0.10 weight percent to about 2.00 weight percent of the composition;

vitamin B6 in an amount of from about 0.10 weight percent to about 2.00 weight percent of the composition;

vitamin B7 in an amount of from about 0.10 weight percent to about 3.00 weight percent of the composition;

vitamin B9 in an amount of from about 0.01 weight percent to about 0.10 weight percent of the composition;

vitamin B12 in an amount of from about 1.00 weight percent to about 10.00 weight percent of the composition;

vitamin C in an amount of from about 1.00 weight percent to about 10.00 weight percent of the composition;

vitamin D3 in an amount of from about 0.10 weight percent to about 1.00 weight percent of the composition;

a pharmaceutically-acceptable compound of calcium in an amount of from about 15.00 weight percent to about 25.00 weight percent of the composition;

a pharmaceutically-acceptable compound of magnesium in an amount of from about 5.00 weight percent to about 15.00 weight percent of the composition;

a pharmaceutically-acceptable compound of zinc in an amount of from about 1.00 weight percent to about 5.00 weight percent of the composition;

a pharmaceutically-acceptable compound of selenium in an amount of from about 0.10 weight percent to about 2.00 weight percent of the composition;

a pharmaceutically-acceptable compound of iron in an amount of from about 5.00 weight percent to about 20.00 weight percent of the composition;

a pharmaceutically-acceptable compound of L-carnitine in an amount of from about 10.00 weight percent to about 25.00 weight percent of the composition;

a pharmaceutically-acceptable compound of manganese in an amount of from about 0.10 weight percent to about 1.00 weight percent of the composition;

a pharmaceutically-acceptable compound of chromium in an amount of from about 0.001 weight percent to about 0.10 weight percent of the composition;

a pharmaceutically-acceptable compound of copper in an amount of from about 0.10 weight percent to about 2.00 weight percent of the composition; and

glutathione or pharmaceutically-acceptable salt thereof in an amount of from about 5.00 weight percent to about 20.00 weight percent of the composition.

13 . A method for treating a subject with type | diabetes or type II diabetes or a subject diagnosed with prediabetes, the method comprising administering to the subject a therapeutically effective amount of a composition comprising:

vitamin B1 in an amount of from about 0.005 weight percent to about 0.10 weight percent of the composition;

vitamin B2 in an amount of from about 0.005 weight percent to about 0.10 weight percent of the composition;

vitamin B3 in an amount of from about 0.05 weight percent to about 0.50 weight percent of the composition;

vitamin B5 in an amount of from about 0.01 weight percent to about 0.50 weight percent of the composition;

vitamin B6 in an amount of from about 0.01 weight percent to about 0.50 weight percent of the composition;

vitamin B7 in an amount of from about 0.010 weight percent to about 0.50 weight percent of the composition;

vitamin B9 in an amount of from about 0.001 weight percent to about 0.10 weight percent of the composition;

vitamin B12 in an amount of from about 0.05 weight percent to about 0.50 weight percent of the composition;

vitamin C in an amount of from about 1.00 weight percent to about 10.00 weight percent of the composition;

vitamin D3 in an amount of from about 0.01 weight percent to about 0.50 weight percent of the composition;

a pharmaceutically-acceptable compound of calcium in an amount of from about 10.00 weight percent to about 35.00 weight percent of the composition;

a pharmaceutically-acceptable compound of magnesium in an amount of from about 15.00 weight percent to about 35.00 weight percent of the composition;

a pharmaceutically-acceptable compound of zinc in an amount of from about 0.10 weight percent to about 2.00 weight percent of the composition;

a pharmaceutically-acceptable compound of selenium in an amount of from about 0.01 weight percent to about 0.50 weight percent of the composition;

a pharmaceutically-acceptable compound of iron in an amount of from about 0.05 weight percent to about 5.00 weight percent of the composition; and

a pharmaceutically-acceptable compound of L-carnitine in an amount of from about 10.00 weight percent to about 30.00 weight percent of the composition.

14 . A method for treating a subject with type I diabetes or type II diabetes or a subject diagnosed with prediabetes, the method comprising administering to the subject a therapeutically effective amount of a composition comprising:

vitamin B1 in an amount of from about 0.50 weight percent to about 3.00 weight percent of the composition;

vitamin B2 in an amount of from about 0.50 weight percent to about 3.00 weight percent of the composition;

vitamin B3 in an amount of from about 1.00 weight percent to about 3.00 weight percent of the composition;

vitamin B5 in an amount of from about 0.10 weight percent to about 2.00 weight percent of the composition;

vitamin B6 in an amount of from about 0.10 weight percent to about 2.00 weight percent of the composition;

vitamin B7 in an amount of from about 0.10 weight percent to about 3.00 weight percent of the composition;

vitamin B9 in an amount of from about 0.01 weight percent to about 0.10 weight percent of the composition;

vitamin B12 in an amount of from about 1.00 weight percent to about 10.00 weight percent of the composition;

vitamin C in an amount of from about 1.00 weight percent to about 10.00 weight percent of the composition;

vitamin D3 in an amount of from about 0.10 weight percent to about 1.00 weight percent of the composition;

a pharmaceutically-acceptable compound of calcium in an amount of from about 15.00 weight percent to about 25.00 weight percent of the composition;

a pharmaceutically-acceptable compound of magnesium in an amount of from about 5.00 weight percent to about 15.00 weight percent of the composition;

a pharmaceutically-acceptable compound of zinc in an amount of from about 1.00 weight percent to about 5.00 weight percent of the composition;

a pharmaceutically-acceptable compound of selenium in an amount of from about 0.10 weight percent to about 2.00 weight percent of the composition;

a pharmaceutically-acceptable compound of iron in an amount of from about 5.00 weight percent to about 20.00 weight percent of the composition;

a pharmaceutically-acceptable compound of L-carnitine in an amount of from about 10.00 weight percent to about 25.00 weight percent of the composition;

a pharmaceutically-acceptable compound of manganese in an amount of from about 0.10 weight percent to about 1.00 weight percent of the composition;

a pharmaceutically-acceptable compound of chromium in an amount of from about 0.001 weight percent to about 0.10 weight percent of the composition;

a pharmaceutically-acceptable compound of copper in an amount of from about 0.10 weight percent to about 2.00 weight percent of the composition; and

glutathione or a pharmaceutically-acceptable salt thereof in an amount of from about 5.00 weight percent to about 20.00 weight percent of the composition.

Continuity (4)
Continuation In Part PCTUS2023066587 · May 4, 2023
Provisional Application 63416767 · Oct 17, 2022
Provisional Application 63364210 · May 5, 2022
Related Publication 20250057842A1 · Feb 20, 2025
References Cited (15)
US 10828313B2 · Salomonsson et al. · 2020 [cited by applicant]
US 20130344167A1 · Chery et al. · 2013 [cited by applicant]
US 20140161784A1 · Westerlund et al. · 2014 [cited by applicant]
US 20160101081A1 · Pan et al. · 2016 [cited by applicant]
US 20160235822A1 · Holstein et al. · 2016 [cited by applicant]
US 20170056463A1 · Cohen · 2017 [cited by examiner]
US 20210353578A1 · Dabdoub · 2021 [cited by applicant]
GB 2585619A · 2021 [cited by applicant]
JP H10273442A · 1998 [cited by applicant]
WO 2020231906A1 · 2020 [cited by applicant]
WO 2021142157A1 · 2021 [cited by applicant]
Legman et al., “Investigating the causes for decreased levels of glutathione in individuals with type II diabetes,” Plos One, doc. No. 0118436, 19 pp., 2015. [cited by examiner]
Jain et al., “Vitamin E, its beneficial role in diabetes mellitus (DM) and its complications,” Journal of Clinical and Diagnostic Research, 6(10):1624-1628, 2012. [cited by examiner]
Nemzer et al., “Betalainic and nutritional profiles of pigment-enriched red beet root ( [cited by examiner]
International Search Report for application PCT/US2023/066587 mailed Sep. 12, 2023. [cited by applicant]